On October 15, Pfizer Pharmaceuticals announced that HYMPAVZI has recently been approved by the US Food and Drug Administration to regularly treat patients with hemophilia A or hemophilia B without coagulation factor inhibitors to reduce the incidence of bleeding. HYMPAVZI is Pfizer's second hemophilia treatment approved by the FDA this year.

Zhitongcaijing · 10/15 02:49
On October 15, Pfizer Pharmaceuticals announced that HYMPAVZI has recently been approved by the US Food and Drug Administration to regularly treat patients with hemophilia A or hemophilia B without coagulation factor inhibitors to reduce the incidence of bleeding. HYMPAVZI is Pfizer's second hemophilia treatment approved by the FDA this year.